CALYPTE BIOMEDICAL CORP (CIK: 0000899426) EDGAR, Information, Filings... CompaniesBIO.Com

CALYPTE BIOMEDICAL CORP

Mailing address
5000 HOPYARD ROAD, SUITE 480, PLEASANTON, Delaware, 94588
Phone
9257307200
State location
California
State of incorporation
Delaware
Fiscal year end
December 31
SIC
3826 - (CF Office: Office of Life Sciences) LABORATORY ANALYTICAL INSTRUMENTS
Filings
N/A

CALYPTE BIOMEDICAL CORP (CIK: 0000899426) is an American company incorporated in the state of California. Head office is located at 5000 HOPYARD ROAD, SUITE 480, PLEASANTON, California, 94588. Work in the industry 3826 - (CF Office: Office of Life Sciences) LABORATORY ANALYTICAL INSTRUMENTS. CALYPTE BIOMEDICAL CORP is a public company and trade via Over-The-Counter (OTC).

Owner	Filings	Transaction Date	Type of Owner
Edilashvili Kartlos	0001483901	Feb-01-2010	director
Al Yousefi Tareq	0001559468	Sep-24-2009	director
TAYLOR DONALD N	0001438227	Jun-16-2008	officer: President and CEO
MINK RONALD WILLIAM	0001409198	Aug-06-2007	officer: Chief Science Officer
CLARK JOHN DANIEL	0001409199	Aug-06-2007	officer: VP-Sales and Marketing
KARAS ADEL	0001400698	May-08-2007	director
Alsuwaidi Ahmed Abdulla Deemas	0001416731	Mar-28-2007	10 percent owner
Ahmed Mohamed	0001416933	Mar-28-2007	10 percent owner
Khidasheli David	0001416991	Mar-28-2007	10 percent owner
Sulaiman Mohamed Yousif Ahmed Saleh	0001417247	Mar-28-2007	10 percent owner
DOTSON JERROLD DUANE	0001388853	Feb-01-2007	officer: VP Fin & Admin, Corp Secretary
GWIN THEODORE R	0001338004	Oct-03-2005	officer: Chief Financial Officer
GALE ROGER I	0001308696	Nov-15-2004	director, 10 percent owner
SOULIMOV MAXIM A	0001285971	Apr-02-2004	director
GEORGE JAMES RICHARD	0001276185	Jan-20-2004	officer: President and CEO
VAN MAANEN RICHARD R	0001276528	Jan-20-2004	officer: Vice President of Operations
MARR TECHNOLOGIES BV	0001262853	Sep-30-2003	10 percent owner
OYAKAWA JAY	0001233344	Jun-03-2003	officer: Pres and Chief Oper. Officer
CATALDO ANTHONY J	0000905279	May-29-2003	director, officer: Executive Chairman
FREIMAN PAUL E	0001184160	May-29-2003	director
NOVITCH MARK	0001184531	May-29-2003	director
KATZ NANCY E	0001189692	May-29-2003	director, officer: Pres. and Chief Exec. Officer
BROUNSTEIN RICHARD D	0001189694	May-29-2003	officer: Exec VP and Chief Fin. Officer
RANDAWA ZAFAR J	0001189697	May-29-2003	director
KREVANS JULIUS R	0001195763	May-29-2003	director
DIPIETRO JOHN J	0001208831	May-29-2003	director
HARRISON DIAN J	0001219322	May-29-2003	director

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by CALYPTE BIOMEDICAL CORP

Filings	Format	Description	Filed/Effective	File/Film Number
REVOKED	Document	Acc-no: 9999999997-15-007431 (34 Act) Size: KB	Apr-06-2015	001-32280 15752578
8-K	Document	Current report filing Acc-no: 0001437749-14-017513 (34 Act) Size: KB	Sep-26-2014	001-32280 141124339
10-K	Document	Annual report pursuant to section 13 and 15(d) Acc-no: 0001437749-14-011782 (34 Act) Size: KB	Jun-24-2014	001-32280 14938034
8-K	Document	Current report filing Acc-no: 0001437749-14-004521 (34 Act) Size: KB	Mar-18-2014	001-32280 14701809
DEF 14A	Document	Definitive proxy statements Acc-no: 0001437749-14-003094 (34 Act) Size: KB	Feb-28-2014	001-32280 14654718
UPLOAD	Document	Acc-no: 0000000000-14-009466 ( Act) Size: KB	Feb-25-2014
CORRESP	Document	A correspondence can be sent as a document with another submission type or can be sent as a separate submission. Acc-no: 0001437749-14-001995 ( Act) Size: KB	Feb-12-2014
UPLOAD	Document	Acc-no: 0000000000-14-007085 ( Act) Size: KB	Feb-11-2014
PRE 14A	Document	Preliminary proxy statement not related to a contested matter or merger/acquisition Acc-no: 0001437749-14-001027 (34 Act) Size: KB	Jan-27-2014	001-32280 14547141
8-K	Document	Current report filing Acc-no: 0001437749-14-000636 (34 Act) Size: KB	Jan-15-2014	001-32280 14530375
NTN 10K	Document	Acc-no: 0001437749-13-003949 (34 Act) Size: KB	Apr-04-2013	001-32280 13741154
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001140361-13-005731 (34 Act) Size: KB	Feb-11-2013	005-50235 13591430
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001140361-13-005725 (34 Act) Size: KB	Feb-11-2013	005-50235 13591241
8-K	Document	Current report filing Acc-no: 0001437749-13-000110 (34 Act) Size: KB	Jan-03-2013	001-32280 13505142
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001437749-13-000058 ( Act) Size: 0 KB	Jan-02-2013
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001437749-13-000057 ( Act) Size: 0 KB	Jan-02-2013
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001437749-13-000055 ( Act) Size: 0 KB	Jan-02-2013
3	Document	Initial statement of beneficial ownership of securities Acc-no: 0001437749-12-013323 ( Act) Size: 0 KB	Dec-31-2012
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001437749-12-013311 (34 Act) Size: KB	Dec-31-2012	001-32280 121293701
NT 10-Q	Document	Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB Acc-no: 0001437749-12-011843 (34 Act) Size: KB	Nov-15-2012	001-32280 121208754

Recent 20 filings. View all CALYPTE BIOMEDICAL CORP filings

Overall rating 5.0

Aug 22, 2022

Jean Bishop

Very good communication and delivery made within the timeframe I was advised of

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Ryan Storey

Huge help thank you for your help .. y'all make it so much easier

CALYPTE BIOMEDICAL CORP overview
CALYPTE BIOMEDICAL CORP job
CALYPTE BIOMEDICAL CORP stock
CALYPTE BIOMEDICAL CORP ownership
CALYPTE BIOMEDICAL CORP CEO
CALYPTE BIOMEDICAL CORP documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.